What is Allogene Therapeutics Inc (ALLO) stock price today?

Allogene Therapeutics Inc (ALLO) currently trades at $2.13 per share. The stock has a market capitalization of $725.79M and a P/E ratio of —x.

Is ALLO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Allogene Therapeutics Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

ALLO

Allogene Therapeutics Inc

NASDAQ: ALLO · HEALTHCARE · BIOTECHNOLOGY

$2.13

+0.95% today

Updated 2026-04-30

Market cap

$725.79M

P/E ratio

—

P/S ratio

7,784.36x

EPS (TTM)

$-0.87

Dividend yield

—

52W range

$1 – $4

Volume

10.3M

Market cap

$725.79M

P/E ratio

—

P/S ratio

7,784.36x

EPS (TTM)

$-0.87

Dividend yield

—

52W range

$1 – $4

Volume

10.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$8.65

+306.10%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy10 Buy1 Hold0 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-27.60M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$243000.00	$95000.00	$22000.00	$0.00	$0.00
Net income	$-329.81M	$-327.26M	$-257.59M	$-190.89M	$-38.81M
EPS	—	—	—	—	$-0.87
Free cash flow	$-225.71M	$-239.25M	$-200.99M	$-149.63M	$-27.60M
Profit margin	-135,726.34%	-344,489.47%	-1,170,863.64%	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-16	CHANG, DAVID D	Sale	47,763	$2.47
2026-03-16	BENESKI, BENJAMIN MACHINAS	Sale	4,835	$2.47
2026-03-02	BENESKI, BENJAMIN MACHINAS	Sale	7,132	$2.60

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ALLO	$725.79M	23	3.7	3.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Allogene Therapeutics Inc trades at $2.13. Our Smart Value Score of 23/100 indicates the stock is weak.

Frequently asked questions

What is Allogene Therapeutics Inc's stock price?

Allogene Therapeutics Inc (ALLO) trades at $2.13.

Is Allogene Therapeutics Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Allogene Therapeutics Inc (ALLO)?

The analyst target price is $8.65, representing +306.1% upside from the current price of $2.13.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7,784.36x

ROE-53.40%

Beta0.54

50D MA$2.41

200D MA$1.61

Shares out0.34B

Float0.19B

Short ratio—

Avg volume10.3M

Performance

1 week-7.79%

1 month-16.80%

3 months+15.76%

YTD+55.47%

1 year—

3 years—

5 years—

Compare

ALLO vs LLY →ALLO vs JNJ →ALLO vs ABBV →Stock screener →